Cat. No：GM-C29783
Product：H_IL-31RA OSMR Baf3 Cell Line
Cat. No：GM-C29783
Product：H_IL-31RA OSMR Baf3 Cell Line
Cell Growth Medium：RPMI 1640+10% FBS+1% P.S+2 ng/mL IL-31+50 μg/mL G418+0.25 μg/mL Puromycin
Cell Freezing Medium：90% FBS+10% DMSO
Assay Buffer：DMEM+1% FBS+1% P.S
Interleukin-31 (IL-31) is a novel cytokine that belongs to the IL-6 cytokine family, with its receptor being similar to the IL-6 receptor. It is primarily secreted by activated CD4+ T lymphocytes, especially activated Th2 cells, mast cells, macrophages, and dendritic cells. IL-31 mainly regulates cell-mediated immunity in the skin by perceiving itch through the peripheral nervous system, modulates lung immunity by increasing airway inflammation, and adjusts intestinal immunity by defending against microbes.
IL-31 forms a heterodimer complex signaling through the IL31RA and OSMR (oncostatin M receptor) receptors, closely associated with chronic pruritic skin diseases like atopic dermatitis. Monoclonal antibodies targeting IL-31 or its receptor can effectively reduce itching and sleep disturbances, improve skin lesions, and minimize the use of topical steroids.
BA/F3 cells, dependent on IL-3 for growth, can be sustained by IL-31 protein instead of IL-3. Blocking this action with IL-31-related antagonists leads to concentration-dependent cell death. Therefore, evaluating the activity of IL-31-related inhibitors can be done by assessing cell viability.
Cat. No：GM-C29783
Product：H_IL-31RA OSMR Baf3 Cell Line
Cell Growth Medium：RPMI 1640+10% FBS+1% P.S+2 ng/mL IL-31+50 μg/mL G418+0.25 μg/mL Puromycin
Cell Freezing Medium：90% FBS+10% DMSO
Assay Buffer：DMEM+1% FBS+1% P.S
Interleukin-31 (IL-31) is a novel cytokine that belongs to the IL-6 cytokine family, with its receptor being similar to the IL-6 receptor. It is primarily secreted by activated CD4+ T lymphocytes, especially activated Th2 cells, mast cells, macrophages, and dendritic cells. IL-31 mainly regulates cell-mediated immunity in the skin by perceiving itch through the peripheral nervous system, modulates lung immunity by increasing airway inflammation, and adjusts intestinal immunity by defending against microbes.
IL-31 forms a heterodimer complex signaling through the IL31RA and OSMR (oncostatin M receptor) receptors, closely associated with chronic pruritic skin diseases like atopic dermatitis. Monoclonal antibodies targeting IL-31 or its receptor can effectively reduce itching and sleep disturbances, improve skin lesions, and minimize the use of topical steroids.
BA/F3 cells, dependent on IL-3 for growth, can be sustained by IL-31 protein instead of IL-3. Blocking this action with IL-31-related antagonists leads to concentration-dependent cell death. Therefore, evaluating the activity of IL-31-related inhibitors can be done by assessing cell viability.
